Analysed RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) News Sources
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
23-08-2026
fool.com
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run
26-08-2026
yahoo.com
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
22-09-2026
yahoo.com
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Progress In Prader-Willi And Genetically Defined Obesity Therapies
13-10-2026
yahoo.com
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
13-10-2026
yahoo.com
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
21-10-2026
yahoo.com
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
21-10-2026
yahoo.com
What is the current price of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The current price of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is $92.18.
RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) absolute price change since previous trading day?
The absolute price change of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) since the previous trading day is $2.71.
RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) percentage price change since previous trading day?
The percentage price change of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) since the previous trading day is 3.0289%.
What is the most recent average sentiment score for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The most recent average sentiment score for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The most recent sentiment for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is .
SEC-8K** Filing Available For RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.